Future Offspring Costs in Economic Evaluation Evelyn VerbekeJeroen Luyten Current Opinion 29 October 2021 Pages: 141 - 147
Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency Gemma E. ShieldsMark WilberforceLinda M. Davies Practical Application 29 October 2021 Pages: 149 - 156
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents Cate BaileyKim DalzielThe Quality Of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA) Project Team Review Article Open access 05 November 2021 Pages: 157 - 182
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review Thitima KongnakornGrammati SarriXinke Zhang Systematic Review Open access 01 October 2021 Pages: 183 - 201
The Utility of a Rapid Review Evaluation Process to a National HTA Agency Áine VarleyLesley TilsonMichael Barry Original Research Article Open access 12 October 2021 Pages: 203 - 214
The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions Yan MengPhilip M. ClarkeIlias Goranitis Original Research Article 21 October 2021 Pages: 215 - 223
Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness? James D. ChambersNikoletta M. MargaretosXin Ye Original Research Article 26 October 2021 Pages: 225 - 232
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS Megan Perry-DuxburyJames LomasPieter van Baal Original Research Article Open access 26 October 2021 Pages: 233 - 239